Sonnet Biotherapeutics Holdings Inc - ESG Rating & Company Profile powered by AI
Jump to the bottom of this page for potential risks for Sonnet Biotherapeutics Holdings Inc based on industry, geography and size. If you are employed by Sonnet Biotherapeutics Holdings Inc and you would like to use your Sustainability aseessment, please get in touch. This webpage displays a zero-cost Sustainability analysis for Sonnet Biotherapeutics Holdings Inc.
Sonnet Biotherapeutics Holdings Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 3.6; made up of an environmental score of 0.0, social score of 2.7 and governance score of 8.0.
3.6
Low ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
... | ... | ... | |
1132 | Taro Pharmaceutical Industries Ltd | 3.7 | Medium |
1132 | Traphaco JSC | 3.7 | Medium |
1144 | Sonnet Biotherapeutics Holdings Inc | 3.6 | Medium |
1144 | CellSeed Inc | 3.6 | Medium |
1144 | Cellectar Biosciences Inc | 3.6 | Medium |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Sonnet Biotherapeutics Holdings Inc have an accelerator or VC vehicle to help deliver innovation?
Does Sonnet Biotherapeutics Holdings Inc disclose current and historical energy intensity?
Does Sonnet Biotherapeutics Holdings Inc report the average age of the workforce?
Does Sonnet Biotherapeutics Holdings Inc reference operational or capital allocation in relation to climate change?
Does Sonnet Biotherapeutics Holdings Inc disclose its ethnicity pay gap?
Does Sonnet Biotherapeutics Holdings Inc disclose cybersecurity risks?
Does Sonnet Biotherapeutics Holdings Inc offer flexible work?
Does Sonnet Biotherapeutics Holdings Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Sonnet Biotherapeutics Holdings Inc disclose the number of employees in R&D functions?
Does Sonnet Biotherapeutics Holdings Inc conduct supply chain audits?
Does Sonnet Biotherapeutics Holdings Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Sonnet Biotherapeutics Holdings Inc conduct 360 degree staff reviews?
Does Sonnet Biotherapeutics Holdings Inc disclose the individual responsible for D&I?
Does Sonnet Biotherapeutics Holdings Inc disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Sonnet Biotherapeutics Holdings Inc disclose current and / or historical scope 2 emissions?
Does Sonnet Biotherapeutics Holdings Inc disclose water use targets?
Does Sonnet Biotherapeutics Holdings Inc have careers partnerships with academic institutions?
Did Sonnet Biotherapeutics Holdings Inc have a product recall in the last two years?
Does Sonnet Biotherapeutics Holdings Inc disclose incidents of discrimination?
Does Sonnet Biotherapeutics Holdings Inc allow for Work Councils/Collective Agreements to be formed?
Has Sonnet Biotherapeutics Holdings Inc issued a profit warning in the past 24 months?
Does Sonnet Biotherapeutics Holdings Inc disclose parental leave metrics?
Does Sonnet Biotherapeutics Holdings Inc disclose climate scenario or pathway analysis?
Does Sonnet Biotherapeutics Holdings Inc disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Sonnet Biotherapeutics Holdings Inc disclose the pay ratio of women to men?
Does Sonnet Biotherapeutics Holdings Inc support suppliers with sustainability related research and development?
Does Sonnet Biotherapeutics Holdings Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Sonnet Biotherapeutics Holdings Inc reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Sonnet Biotherapeutics Holdings Inc involved in embryonic stem cell research?
Does Sonnet Biotherapeutics Holdings Inc disclose GHG and Air Emissions intensity?
Does Sonnet Biotherapeutics Holdings Inc disclose its waste policy?
Does Sonnet Biotherapeutics Holdings Inc report according to TCFD requirements?
Does Sonnet Biotherapeutics Holdings Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Sonnet Biotherapeutics Holdings Inc disclose energy use targets?
Does Sonnet Biotherapeutics Holdings Inc disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Sonnet Biotherapeutics Holdings Inc have a policy relating to cyber security?
Have a different question?
Potential Risks for Sonnet Biotherapeutics Holdings Inc
These potential risks are based on the size, segment and geographies of the company.
Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6 for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy. It has a license agreement with New Life Therapeutics PTE, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin 6. Sonnet BioTherapeutics Holdings, Inc. is based in Princeton, New Jersey.